GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Oragenics OGEN · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.35

+1.62%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Oragenics

From its filings with the US Securities and Exchange Commission

SEC filings

Oragenics is based in Lakewood Ranch, Florida and is incorporated in Florida. Its shares trade on NYSE under the ticker OGEN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2023, it reported revenue of $37,653.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
9 Jul 2003
Employees
7
Head office
9015 TOWN CENTER PARKWAY, LAKEWOOD RANCH, FL, 34202
Incorporated in
FL
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Charles PopeExecutive Chairman of the Board, since 2010$137,850
  • Ms. Janet HuffmanPresident, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary$363,700
  • Dr. James KellyChief Medical Officer
  • Dr. William PeacockChief Clinical Officer
  • Ms. Natasha GiordanoDirector
  • Dr. Alan DuntonIndependent Director$100,350
  • Mr. John GandolfoIndependent Director$62,550
  • Mr. Robert KoskiIndependent Director$75,350
  • Dr. Frederick TellingIndependent Director, since 2010$111,500
  • Mr. Tirth PatelVice President, since 2022

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Oragenics focuses on novel antibiotics and treatments for infectious disease in the Health Care sector.
  • Oragenics has developed OG716 as an antibiotic and AG013 for oral mucositis treatment.
  • Oragenics is developing TerraCoV2 immunization product candidate for infectious disease.

Weaknesses

  • Oragenics has only 7 full-time employees in Tampa, Florida.
  • Oragenics went public in 2003 with limited resources for development.
  • Oragenics has a small product portfolio including LPT3-04 and SMaRT Replacement Therapy.

Opportunities

  • Oragenics can expand its focus on TerraCoV2 immunization product candidate for global health needs.
  • Oragenics can leverage its biopharmaceutical expertise in the Health Care sector for new partnerships.
  • Oragenics can target the growing market for oral mucositis treatments in cancer patients.

Threats

  • Oragenics faces competition from larger biopharmaceutical companies in the Health Care sector.
  • Oragenics must navigate regulatory challenges for new antibiotic approvals in the US.
  • Oragenics needs to secure additional funding for product development and clinical trials.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.